Leica Biosystems has acquired privately held DNA fluorescent in situ hybridization (FISH) probes and target labeling reagents provider Kreatech Diagnostics for an undisclosed amount. Kreatech will join Leica Biosystems’ Advanced Staining business unit based in the UK. The combined business will develop targeted biomarker menus for Leica’s instrument platforms. The acquisition will enable Leica Biosystems “to better serve our cytogenetics and anatomic pathology customers,” said Dr. Matthias G. Weber, president of Leica Biosystems. “It will also enable us to actively support the future development of personalized medicine by research and drug development companies. By standardizing and supporting the interpretation of results with our Aperio ePathology imaging solutions, we will provide our customers with the ability to effectively and efficiently manage ever more complex diagnostic requirements.” Leica Biosystems is a provider of ThermoBrite and Bond systems for labeling tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories. For more information, visit: www.leicabiosystems.com or www.kreatech.com